Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers
Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh
Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh
View: Text | PDF
Research Article Inflammation Oncology

Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers

  • Text
  • PDF
Abstract

Carcinomas are common in humans but rare among closely related “great apes.” Plausible explanations, including human-specific genomic alterations affecting the biology of sialic acids, are proposed, but causality remains unproven. Here, an integrated evolutionary genetics-phenome-transcriptome approach studied the role of SIGLEC12 gene (encoding Siglec-XII) in epithelial transformation and cancer. Exogenous expression of the protein in cell lines and genetically engineered mice recapitulated approximately 30% of the human population in whom the protein is expressed in a form that cannot bind ligand because of a fixed, homozygous, human-universal missense mutation. Siglec-XII–null cells/mice recapitulated the remaining approximately 70% of the human population in whom an additional polymorphic frameshift mutation eliminates the entire protein. Siglec-XII expression drove several pro-oncogenic phenotypes in cell lines and increased tumor burden in mice challenged with chemical carcinogen and inflammation. Transcriptomic studies yielded a 29-gene signature of Siglec-XII–positive disease and when used as a computational tool for navigating human data sets, pinpointed with surprising precision that SIGLEC12 expression (model) recapitulates a very specific type of colorectal carcinomas (disease) that is associated with mismatch-repair defects and inflammation, disproportionately affects European Americans, and carries a favorable prognosis. They revealed a hitherto-unknown evolutionary genetic mechanism for an ethnic/environmental predisposition of carcinogenesis.

Authors

Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh

×

Figure 4

Transgenic knockin SIGLEC12 mice are at greater risk of inflammation-associated CRCs.

Options: View larger image (or click on image) Download as PowerPoint
Transgenic knockin SIGLEC12 mice are at greater risk of inflammation-ass...
(A) An overview of experimental design for the induction of Siglec-XII expression by serial administration of tamoxifen followed by carcinogenesis protocol consisting of a single administration of azoxymethane (AOM) and 4 cycles of dextran sodium sulfate (DSS). (B) Representative pictures of colonic tissue from control and Siglec-XII–expressing mice subjected to tamoxifen administration and carcinogenesis protocol (AOM/DSS). Scale bar: 1 cm. The complete panel of pictures of colonic tissue is shown in Supplemental Figure 4. (C and D) Comparison of the number of tumors (C) and tumor size (D) in control (N = 7) and Siglec-XII–expressing mice (N = 7) subjected to tamoxifen administration and carcinogenesis protocol. Error bars indicate ± SD. (E) Representative pictures of H&E-stained colonic tissue from control and Siglec-XII–expressing mice subjected to tamoxifen administration and carcinogenesis protocol. The boxed areas (top) are shown at higher magnification (bottom). Arrows indicate immune cell infiltrates. Scale bars: 100 μm (top), 50 μm (bottom). Statistics: P values were calculated by 2-tailed t test using GraphPad Prism. P value < 0.05 was considered significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts